Mouse Monoclonal IFNAR1 Antibody

IFNAR1 (Interferon Alpha and Beta Receptor Subunit 1) is a critical component of the type I interferon (IFN) receptor complex, which mediates cellular responses to type I IFNs, including IFN-α and IFN-β. As a transmembrane protein, IFNAR1 pairs with IFNAR2 to form a functional receptor that binds IFN ligands, initiating downstream JAK-STAT signaling. This pathway activates interferon-stimulated genes (ISGs) involved in antiviral defense, immune modulation, and cell proliferation regulation. Antibodies targeting IFNAR1 are valuable tools for studying its role in innate immunity, inflammatory diseases, and viral infections. Neutralizing IFNAR1 antibodies can block IFN signaling, offering therapeutic potential in autoimmune disorders (e.g., lupus, multiple sclerosis) where excessive IFN activity drives pathology. Conversely, agonist antibodies may enhance IFN responses in contexts like cancer immunotherapy. Researchers also use IFNAR1 antibodies for detecting receptor expression, internalization, or signaling dynamics in vitro and in vivo. Dysregulated IFNAR1 expression or signaling is implicated in chronic inflammation, viral evasion mechanisms, and resistance to IFN-based therapies, making it a biomarker and therapeutic target. Recent studies explore IFNAR1-targeting strategies in COVID-19. oncology, and autoimmune drug development, highlighting its broad biomedical relevance.